Although data on ONC206 concentrations in H3 K27M gliomas are currently the subject of investigation within a Phase I trial,9 oral ONC206 doses of 50–150 mg have been shown to result in peak plasma concentrations of ~0.5–1.5 μM.10 Given that ONC206 penetrates the blood–brain barrier, this may support the notion that D2R antagonism contributes to ONC206 cytotoxicity, in addition to other mechanisms such as Clp protease activation. Here, DRD2 is linked to glioma.